RU2010153576A - Противоопухолевые эффекты комбинаций каннабиноидных соединений - Google Patents
Противоопухолевые эффекты комбинаций каннабиноидных соединений Download PDFInfo
- Publication number
- RU2010153576A RU2010153576A RU2010153576/15A RU2010153576A RU2010153576A RU 2010153576 A RU2010153576 A RU 2010153576A RU 2010153576/15 A RU2010153576/15 A RU 2010153576/15A RU 2010153576 A RU2010153576 A RU 2010153576A RU 2010153576 A RU2010153576 A RU 2010153576A
- Authority
- RU
- Russia
- Prior art keywords
- cbd
- thc
- combination
- cannabidiol
- tetrahydrocannabinol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
Abstract
1. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) в соотношении от 5:1 до 1:5 для применения в лечении опухоли головного мозга. ! 2. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где лечение опухоли головного мозга заключается в снижении выживаемости клеток, подавлении клеточного роста или уменьшении объема опухоли. ! 3. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где ТГК и КБД находятся в соотношении от 2:1 до 1:2. ! 4. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по П.1, где ТГК и КБД находятся в соотношении приблизительно 1:1. ! 5. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где общее содержание каннабиноида находится в пределах от 5 до 100 мг. ! 6. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где каждый каннабиноид используют в количестве, которое будет считаться недостаточным в случае их применения по отдельности. ! 7. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где опухоль головного мозга представляет собой глиому. ! 8. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.7, где опухоль головного мозга представляет собой полиморфную глиобластому (ПГБ). ! 9. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где ТГК и КБД присутствуют в качестве растительных экстрактов, в качестве чистых компонентов или их комбинации. ! 10. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.9, где растительный экстракт находится в фо
Claims (13)
1. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) в соотношении от 5:1 до 1:5 для применения в лечении опухоли головного мозга.
2. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где лечение опухоли головного мозга заключается в снижении выживаемости клеток, подавлении клеточного роста или уменьшении объема опухоли.
3. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где ТГК и КБД находятся в соотношении от 2:1 до 1:2.
4. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по П.1, где ТГК и КБД находятся в соотношении приблизительно 1:1.
5. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где общее содержание каннабиноида находится в пределах от 5 до 100 мг.
6. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где каждый каннабиноид используют в количестве, которое будет считаться недостаточным в случае их применения по отдельности.
7. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где опухоль головного мозга представляет собой глиому.
8. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.7, где опухоль головного мозга представляет собой полиморфную глиобластому (ПГБ).
9. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.1, где ТГК и КБД присутствуют в качестве растительных экстрактов, в качестве чистых компонентов или их комбинации.
10. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по п.9, где растительный экстракт находится в форме растительного лекарственного вещества.
11. Комбинация каннабиноидов тетрагидроканнабинола (ТГК) и каннабидиола (КБД) по любому из предшествующих пунктов, где один или несколько каннабиноидов вводят раздельно, последовательно или одновременно друг с другом.
12. Применение каннабидиола (КБД) для увеличения эффективности тетрагидроканнабинола (ТГК) при лечении опухоли головного мозга.
13. Применение КБД по п.12 для уменьшения выживаемости клеток глиомы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0810195.8 | 2008-06-04 | ||
| GB0810195.8A GB2471987B (en) | 2008-06-04 | 2008-06-04 | Anti-tumoural effects of cannabinoid combinations |
| PCT/GB2009/050621 WO2009147439A1 (en) | 2008-06-04 | 2009-06-04 | Anti-tumoural effects of cannabinoid combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010153576A true RU2010153576A (ru) | 2012-07-20 |
| RU2546284C2 RU2546284C2 (ru) | 2015-04-10 |
Family
ID=39638149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010153576/15A RU2546284C2 (ru) | 2008-06-04 | 2009-06-04 | Противоопухолевые эффекты комбинаций каннабиноидных соединений |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8632825B2 (ru) |
| EP (2) | EP2318000A1 (ru) |
| JP (1) | JP5611196B2 (ru) |
| KR (2) | KR20160103148A (ru) |
| CN (1) | CN102083430B (ru) |
| AR (1) | AR072003A1 (ru) |
| AU (1) | AU2009254936B2 (ru) |
| BR (1) | BRPI0913384A2 (ru) |
| CA (1) | CA2726258C (ru) |
| CO (1) | CO6382172A2 (ru) |
| GB (1) | GB2471987B (ru) |
| IL (1) | IL209738B (ru) |
| MX (1) | MX2010012557A (ru) |
| MY (1) | MY156444A (ru) |
| NZ (1) | NZ589228A (ru) |
| RU (1) | RU2546284C2 (ru) |
| SG (2) | SG195650A1 (ru) |
| TW (1) | TWI445531B (ru) |
| UA (1) | UA104426C2 (ru) |
| WO (1) | WO2009147439A1 (ru) |
| ZA (1) | ZA201008556B (ru) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB201117956D0 (en) * | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
| EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| WO2014100231A1 (en) | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| GB2516814B (en) * | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
| PT3062606T (pt) | 2013-10-29 | 2019-07-17 | Biotech Inst Llc | Reprodução, produção, transformação e uso de canábis especial |
| MX387604B (es) * | 2014-05-29 | 2025-03-18 | Insys Pharma Inc | Formulaciones cannabinoides estables. |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| WO2016054268A1 (en) | 2014-09-30 | 2016-04-07 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2016123475A1 (en) | 2015-01-31 | 2016-08-04 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| EP3067058A1 (en) | 2015-03-13 | 2016-09-14 | Farmagens Health Care Srl | Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids |
| BR112017025388A2 (pt) | 2015-05-28 | 2018-08-07 | Tweed Inc. | plantas cannabis tendo expressão modificada de thca sintase |
| US10123973B2 (en) * | 2015-06-11 | 2018-11-13 | Mashhad University Of Medical Science | Liposome composition for cancer treatment |
| US20180185324A1 (en) * | 2015-06-11 | 2018-07-05 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (mm) |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2017013661A1 (en) | 2015-07-22 | 2017-01-26 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
| EP3153160B1 (en) | 2015-10-08 | 2021-08-11 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CN109310648B (zh) * | 2015-10-27 | 2022-06-03 | 杰伊制药公司 | 用于治疗癌症的包含大麻二酚和第二治疗剂的组合物 |
| WO2017091764A1 (en) * | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| AU2018233582B2 (en) * | 2017-03-16 | 2022-04-07 | CannTab Therapeutics, Limited | Modified release multi-layer tablet cannabinoid formulations |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020129043A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis sativa lines and extracts with anti-cancer properties |
| WO2020163775A1 (en) | 2019-02-08 | 2020-08-13 | Srin Therapeutics, Inc. | Cannabinoid compositions and methods of use thereof for immune modulation, immune protection, and treatment of cancer |
| SG11202111809XA (en) * | 2019-04-24 | 2021-11-29 | Inmed Pharmaceuticals Inc | Compositions and methods for use of cannabinoids for neuroprotection |
| CA3078205A1 (en) * | 2019-05-03 | 2020-11-03 | Hfl Partners, Llc Dba Reed's Remedies | Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US20210100737A1 (en) | 2019-10-03 | 2021-04-08 | Starton Therapeutics, Inc. | Transdermal delivery of dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| WO2021070120A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス，インコーポレイテッド | カンナビジオールの経皮送達 |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| IL272078A (en) * | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in treatment |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
| WO2022225658A1 (en) * | 2021-04-19 | 2022-10-27 | The Regents Of The University Of California | Cannabis limits cancer stem cell growth in poorly differentiated cancers |
| WO2023062634A1 (en) * | 2021-10-13 | 2023-04-20 | G.R.I.N Ultra Ltd | Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| KR20250106523A (ko) | 2024-01-03 | 2025-07-10 | 충북대학교 산학협력단 | 인돌３락테이트 화합물을 유효성분으로 포함하는 뇌종양의 예방 또는 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566560B2 (en) * | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| ES2164584A1 (es) * | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
| US20040039048A1 (en) * | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
| ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| US7429457B2 (en) * | 2000-09-14 | 2008-09-30 | The Regents Of The University Of California | Id-1 and Id-2 genes and products as markers of epithelial cancer |
| US7025992B2 (en) * | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
| IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
| WO2003091189A1 (en) * | 2002-04-25 | 2003-11-06 | Virginia Commonwealth University | Cannabinoids |
| US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| GB2418612A (en) * | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| US7638558B2 (en) | 2005-04-01 | 2009-12-29 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
| US7968594B2 (en) * | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
| WO2006124698A2 (en) * | 2005-05-13 | 2006-11-23 | Unimed Pharmaceuticals, Inc. | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
| GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| US9084771B2 (en) * | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
| GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
| GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
-
2008
- 2008-06-04 GB GB0810195.8A patent/GB2471987B/en active Active
-
2009
- 2009-06-03 AR ARP090102000A patent/AR072003A1/es unknown
- 2009-06-03 TW TW098118351A patent/TWI445531B/zh active
- 2009-06-04 CA CA2726258A patent/CA2726258C/en active Active
- 2009-06-04 SG SG2013082474A patent/SG195650A1/en unknown
- 2009-06-04 KR KR1020167022577A patent/KR20160103148A/ko not_active Withdrawn
- 2009-06-04 SG SG2013043096A patent/SG191644A1/en unknown
- 2009-06-04 BR BRPI0913384-4A patent/BRPI0913384A2/pt not_active Application Discontinuation
- 2009-06-04 KR KR1020117000057A patent/KR101801639B1/ko active Active
- 2009-06-04 NZ NZ589228A patent/NZ589228A/xx unknown
- 2009-06-04 WO PCT/GB2009/050621 patent/WO2009147439A1/en not_active Ceased
- 2009-06-04 MY MYPI2010005534A patent/MY156444A/en unknown
- 2009-06-04 AU AU2009254936A patent/AU2009254936B2/en active Active
- 2009-06-04 EP EP09757811A patent/EP2318000A1/en not_active Withdrawn
- 2009-06-04 MX MX2010012557A patent/MX2010012557A/es active IP Right Grant
- 2009-06-04 RU RU2010153576/15A patent/RU2546284C2/ru not_active IP Right Cessation
- 2009-06-04 CN CN200980120759.0A patent/CN102083430B/zh active Active
- 2009-06-04 UA UAA201015971A patent/UA104426C2/ru unknown
- 2009-06-04 US US12/996,124 patent/US8632825B2/en active Active
- 2009-06-04 EP EP20201377.7A patent/EP3785710B1/en active Active
- 2009-06-04 JP JP2011512222A patent/JP5611196B2/ja active Active
-
2010
- 2010-11-29 ZA ZA2010/08556A patent/ZA201008556B/en unknown
- 2010-12-02 IL IL209738A patent/IL209738B/en active IP Right Grant
- 2010-12-15 CO CO10157623A patent/CO6382172A2/es not_active Application Discontinuation
-
2013
- 2013-11-14 US US14/079,994 patent/US20140287067A1/en not_active Abandoned
-
2015
- 2015-01-14 US US14/596,725 patent/US20150313867A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,616 patent/US20200138771A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010153576A (ru) | Противоопухолевые эффекты комбинаций каннабиноидных соединений | |
| Harlev et al. | Anticancer potential of aloes: antioxidant, antiproliferative, and immunostimulatory attributes | |
| RU2012111235A (ru) | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог | |
| Boulaaba et al. | Anticancer effect of Tamarix gallica extracts on human colon cancer cells involves Erk1/2 and p38 action on G2/M cell cycle arrest | |
| Raihan et al. | Evaluation of antitumor activity of Leea indica (Burm. f.) merr extract against Ehrlich ascites carcinoma (EAC) bearing mice | |
| DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
| You et al. | Modulatory effect of fermented papaya extracts on mammary gland hyperplasia induced by estrogen and progestin in female rats | |
| MX2015006370A (es) | Suplementos herbales y metodos para utilizar los mismos. | |
| JP2016501862A5 (ru) | ||
| Jaruchotikamol et al. | Cytoprotective activity of mulberry leaf extract against oxidative stress-induced cellular injury in rats. | |
| Sharma | Nutraceuticals and nutraceutical supplementation criteria in cancer: a literature survey | |
| HRP20161447T1 (hr) | Pripravak koji sadrži ekstrakt zelenog čaja i ekstrakt nara, namijenjen upotrebi u sprječavanju ili usporavanju napredovanja raka prostate | |
| CN103655430A (zh) | 一种具有美白功效的面膜 | |
| Yao et al. | Determination of synergistic effects of polymethoxylated flavone extracts of Jinchen orange peels (Citrus Sinensis Osberk) with amino acids and organic acids using chemiluminescence | |
| Ye et al. | Free radical scavenging activity and anti-inflammatory property of the saponin from seeds of Camellia oleifera abel | |
| WO2008139313A3 (en) | Propofol transparent anaesthetic solution with low venous irritation | |
| Nickavar | Free radical scavenging activities of four Salvia species | |
| RU2522547C1 (ru) | Фармакологическая геропротекторная композиция и способ ее получения | |
| CN103223044A (zh) | 一种中药组合物及其制备方法 | |
| Shinde et al. | In vitro antioxidant activity of ethanolic and chloroform extracts of Tagetes erecta flowers | |
| Capodice et al. | Two case reports on the use of genistein combined polysaccharide (GCP) against bladder cancer recurrence. | |
| Shin et al. | In vitro Antioxidant Activity of Crude Extract from Rubus coreanus $ M_ {IQ} $. | |
| Gaurav | Review: Pharmacological and Medicinal Activity of Active Compounds of Withania somnifera | |
| RU2015100281A (ru) | Фармацевтическая композиция для регенерации печени | |
| CN103316271B (zh) | 中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160605 |